Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 18 de 18
Filtrer
Plus de filtres








Gamme d'année
1.
Braz. J. Pharm. Sci. (Online) ; 59: e22746, 2023. tab, graf
Article de Anglais | LILACS | ID: biblio-1520326

RÉSUMÉ

Abstract The aim of this study was to evaluate tumor necrosis factor alpha (TNF-α), interleukin (IL)- 17A/F levels in the serum of ankylosing spondylitis (AS) patients after anti-TNF therapy, in order to understand how these cytokines are involved in this therapeutic response. Forty-four AS patients were included in the study: thirty using anti-TNF therapy were classified according to their therapy response as responders (15) and non-responders (15) and 14 without anti-TNF therapy were classified as AS control. Fifteen healthy individuals formed the control group. Serum levels of TNF-α were determined using Luminex technology and for IL-17A and IL-17F using ELISA. The non-responder patients presented higher serum levels of TNF-α than the responders and AS control; the same results were found when HLA-B*27 positive or negative patients were separately analyzed. IL-17A and IL17F serum levels were similar for all groups. According to the clinical disease activity, AS patients with BASDAI ≥4 had higher serum levels of TNF-α than AS patients with BASDAI <4. Positive correlation was found between TNF-α levels and BASDAI. In AS patients, TNF-α serum levels were associated with anti-TNF therapy and disease activity independently of HLA-B*27, and IL-17A and IL-17F were not related to anti-TNF treatment


Sujet(s)
Humains , Mâle , Femelle , Patients/classification , Pelvispondylite rhumatismale/anatomopathologie , Facteur de nécrose tumorale alpha/analyse , Interleukine-17/analyse , Polymorphisme génétique , Cytokines/classification , Études d'associations génétiques/instrumentation
2.
Braz. j. pharm. sci ; 52(4): 623-633, Oct.-Dec. 2016. graf
Article de Anglais | LILACS | ID: biblio-951871

RÉSUMÉ

ABSTRACT Pro-inflammatory cytokines and glial cells, especially microglial cells, have been implicated in persistent pain sensitization. Less is known about the role of astrocytes in pain regulation. This study aimed to observe the expression of the astrocytic biomarker glial fibrillary acidic protein (GFAP) and the serum levels of interleukin 1 beta (IL-1ß) and tumor necrosis factor alpha (TNF-α) after short-term administration of central pain relievers in rats not submitted to noxious stimuli. Male Wistar rats were divided into five groups, receiving for nine days- (1) amitriptyline (Amt-10 mg/kg/day, by gavage); (2) gabapentin (Gb-60 mg/kg/day, by gavage; (3) methadone (Me-4.5 mg/kg/day, intraperitoneal route [IP]); (4) morphine (Mo-10 mg/kg/day, IP); or (5) 0.9% saline solution, IP. Brain samples were collected for immunohistochemical study of GFAP expression in the mesencephalon and nucleus accumbens (NAc). The area of GFAP-positive cells was calculated using MetaMorph software and serum levels of IL-1ß and TNF-α were measured by enzyme-linked immunosorbent assay. Serum TNF-α levels were decreased in the groups treated with Mo, Me and Gb, but not in the Amt-treated group. IL-1ß decreased only in rats treated with Me. The astrocytic expression of GFAP was decreased in the brainstem with all drugs, while it was increased in the NAc with Amt, Me and Mo


Sujet(s)
Animaux , Mâle , Rats , Protéine gliofibrillaire acide/analyse , Analgésiques/pharmacologie , Douleur/traitement médicamenteux , Astrocytes/immunologie , Cytokines/classification
3.
Salvador; s.n; 2014. 120 p. ilus, tab.
Thèse de Portugais | LILACS | ID: biblio-1000949

RÉSUMÉ

Neste estudo foi analisada a distribuição de isotipos de imunoglobulinas IgG1, IgG2 e IgE envolvidas na resposta a Leishmania no soro e a expressão de mRNA para IFN-g e IL-4 in situ no baço de cães naturalmente infectados com L.infantum com diferentes perfis de susceptibilidade ou resistência à doença. A atividade sérica de anticorpos do isotipo IgG1 contra Leishmania tendeu a ser maior nos animais com teste cutêneo da Leishmanina negativo e com parasitismo esplênico (grupo infectado potencialmente susceptível, 0,424±0,401) que nos outros grupos: com teste cutêneo da Leishmanina positivo e ausência de parasitismo esplênico (grupo infectado potencialmente resistente, 0,226±0,114), ou com ambos teste cutêneo da Leishmanina e cultura esplênica positivos (grupo em fase indeterminada da doença, 0,234±0,125) ou com ambos os parâmetros negativos (grupo potencialmente não infectado, 0,159±0,044). Essa diferença não foi, contudo estatisticamente significante (ANOVA, P=0,1450). IgG2 específica anti-Leishmania foi maior (ANOVA P=0,0001)...


We analyzed the distribution immunoglobulin isotypes IgG1, IgG2 and IgE involved in the response to Leishmania and the mRNA expression for IFN-g and IL-4 in situ in the spleen of dogs naturally infected with IgG1 antibody anti-Leishmania serum activity was higher in animals with negative Leishmanin skin test and splenic parasitism (infected and potencially susceptible to VL group, 0,424±0,401) than in other groups: positive Leishmanin skin test and negative splenic parasitism (infected and potentially resistant to VL group, 0,226±0,114), or both positive Leishmanin skin test and slpenic parasitism (infected with undefined susceptibility status group, 0234±0,125) or both negative parameters (non-infected group, 0159±0,044). This difference however was not statistically significant (ANOVA, P=0145)...


Sujet(s)
Humains , Cytokines/analyse , Cytokines/classification , Cytokines/immunologie , Leishmaniose viscérale/diagnostic , Leishmaniose viscérale/épidémiologie , Leishmaniose viscérale/immunologie , Leishmaniose viscérale/parasitologie , Leishmaniose viscérale/anatomopathologie , Leishmaniose viscérale/transmission , Leishmaniose viscérale/urine
4.
Rio de Janeiro; s.n; 2013. xviii,128 p. ilus, graf, tab.
Thèse de Portugais | LILACS | ID: lil-751641

RÉSUMÉ

O vírus linfotrópico para células T humanas (HTLV-1) é o principal agente causador da Paraparesia Espástica Tropical / Mielopatia associada ao HTLV-1 (PET/MAH) e da Leucemia da célula T do Adulto (LTA). [...]Fatores da interação HTLV-1/ hospedeiro estão envolvidos no risco de desenvolver doença. A lesão neurológica na PET/MAH parece ser consequência de uma reação inflamatória, desencadeada pelo reconhecimento de células infectadas por linfócitos T citotóxicos, com consequente liberação de citocinas e lesão medular. OBJETIVO: Identificar marcadores genéticos, que possam ajudar no prognóstico e tratamento dos pacientes portadores do HTLV-1. MÉTODOS: Nas amostras de 117 portadores do HTLV-1 assintomáticos e 171 pacientes com acometimento neurológico em acompanhamento na cidade do Rio de Janeiro, foram realizadas as tipificações dos genes do HLA Classe I e II, dos polimorfismos dos genes das citocinas -308TNF-α,-174IL-6, +874IFN-γ, códon 10 e 25TGF-β1 e -1082 - 819-592IL-10, e a quantificação da carga proviral. Os dados foram organizados em um banco de dados no programa SPSS. As frequências alélicas e genotípicas foram obtidas por contagem direta. O equilíbrio de Hardy-Weinberg foi avaliado para os polimorfismos das citocinas no sitio http://bioinfo.iconcologia.net/ubbweb/SNPStats_web, em relação ao HLA foram utilizadas as ferramentas disponíveis no sítio “Los Alamos HIV database tools”. As comparações entre os grupos foram realizadas através de tabelas de contingência 2x2 (quiquadrado, exato de Fisher e odds ratios), valores de p≤0,05 foram considerados significantes...


The human T cell lymphotropic vírus (HTLV-1) is the main causingagent of Tropical Spastic Paraparesis/HTLV-1 Associated Myelopathy (HAM/TSP) aswell as of Adult T Cell Leukemia (ATL). [...] Factorsrelated to the HTLV-1/host interaction may be involved in the risk of developing thediseases. The neurological lesion in HAM/TSP may be the consequence of aninflammatory reaction, triggered by the recognition of infected cells by cytotoxic Tlymphocytes, followed by the release of cytokines and central nervous system lesion.OBJECTIVE: This work aims to identify genetic markers, which may help in theprognosis and treatment of HTLV-1 patients. Methods: The polymorphism of the HLAClass I and II genes, as well as the TNF-α, IL6, IFN-γ, TGF-β and IL-10 cytokinegenes, and the proviral load were analysed in 117 asymptomatic HTLV-1 carriersand 171 HTLV-1 symptomatic carriers from Rio de Janeiro city. Data were organizedinto a database using SPSS. The Hardy-Weinberg equilibrium was evaluated forcytokine polimorphisms using the site http://bioinfo.iconcologia.net/ubbweb/SNPStats_web. The tools available in the site “Los Alamos HIV database tools” were used toanalyze the HLA polimorphisms. Comparisons between groups were made using 2x2contingency tables (Fisher Exact test/ χ2 and odds ratios), p values p≤0,05 wereconsidered significant...


Sujet(s)
Humains , Cytokines/classification , Leucémie à cellules T/diagnostic , Complexe majeur d'histocompatibilité , Paraparésie spastique tropicale , Virus T-lymphotrope humain de type 1/génétique , Technique de Western , Test ELISA
7.
Rev. méd. Hosp. Gen. Méx ; 61(2): 97-102, abr.-jun. 1998. tab, ilus
Article de Espagnol | LILACS | ID: lil-248078

RÉSUMÉ

Se definen qué son las citocinas y se describe el papel de la interleucina-1 como un ejemplo de las fuciones que desempeñan. Actualmente se han encontrado más de 40 citocinas que se han agrupado en 1) factores de crecimiento, 2) interleucinas, 3) interferones, 4) quimiocinas y 5) otras. Hoy en día, mediante transfección genética, se han preparado 11 citocinas para aplicación terapéutica; de éstas, la eritropoyetina, el factor estimulante de colonias granulocito-monocito y el factor estimulante de colonias granulocito-monocito y el factor estimulante de colonias de granulocitos se utilizan con buen éxito para estimular la producción de glóbulos rojos, granulocitos y de monocitos en algunas patologías con daño a la médula ósea. Después de varios años de aplicación clínica, el uso de los interferones alfa, beta y gamma se han visto limitados a infecciones como la hepatitis B o C y algunos tipos de cáncer como la leucemia de células peludas y la leucemia granolocítica crónica. Las otras citocinas, como las interleucinas 2, 3, 4, 6 y el factor estimulante de colonias de monocitos, empiezan a mostrar su utilidad terapéutica en algunos ensayos clínicos. Se espera que en el futuro algunas de ellas, solas o combinadas con otras u otros activadores inmunológicos curen enfermedades como el síndrome de inmunodeficiencia adquirida o el cáncer


Sujet(s)
Cytokines/classification , Cytokines/immunologie , Cytokines/pharmacologie , Facteur de stimulation des colonies de granulocytes/pharmacologie , Facteur de stimulation des colonies de macrophages/pharmacologie , Érythropoïétine/pharmacologie , Interférons/usage thérapeutique , Interférons/pharmacologie , Interleukine-6/pharmacologie , Interleukine-2/pharmacologie , Interleukine-3/pharmacologie
10.
In. Palomo González, Iván; Ferreira Vigoroux, Arturo; Sepúlveda Carvajal, Cecilia; Rosemblatt Silber, Mario; Vergara Castillo, Ulises. Fundamentos de inmunología. Talca, Universidad de Talca, 1998. p.219-70, ilus, tab.
Monographie de Espagnol | LILACS | ID: lil-284809
11.
Braz. j. infect. dis ; Braz. j. infect. dis;1(3): 106-22, Jun. 1997. tab
Article de Anglais | LILACS | ID: lil-247326

RÉSUMÉ

Two important issue regarding the use of immunization to control infections and malignancies in the futureare: 1) the need to render poorly immunogenic, often highly purified, antigens more effective; and 2) the desire to direct the immune response in specific ways to achieve the most relevant response for each disease. The first issue can be solved by a broad range of vaccine adjuvants. The second requires careful selection among the adjuvants to allow directing of the immune response in the most appropriate manner. For exemple, in different settings expansion of a B cell response, cytotoxic T cell response, or enhancement of either a Th1 or Th2 subset response may be desired. These goals are accomplished by the use of several newly developed non-cytokine adjuvants, or by direct injection of the relevant cytokines. Some non-cytokine molecular adjuvants and cytokines used as adjuvants have already been proven effective in animal models and/or in clinical trials. Here, we review the present state of art in the use of vaccine adjuvants for control of various infections diseases.


Sujet(s)
Adjuvants immunologiques/pharmacocinétique , Vaccin BCG/immunologie , Cytomegalovirus/métabolisme , Adjuvant Freund/pharmacocinétique , Immunisation , Lipide A/physiologie , Lipide A/toxicité , Liposomes/immunologie , Paludisme/immunologie , Thymopentine/pharmacocinétique , Cytokines/classification , Cytokines/physiologie , Évaluation de médicament , Hépatite A/immunologie , Hépatite B/immunologie , Herpès/métabolisme , Grippe humaine/immunologie , Grippe humaine/métabolisme , Syndrome d'immunodéficience acquise/immunologie , Syndrome d'immunodéficience acquise/métabolisme
16.
Rev. mex. reumatol ; 10(3): 77-87, mayo-jun. 1995. ilus, tab
Article de Espagnol | LILACS | ID: lil-173928

RÉSUMÉ

Al activarse, los linfocitos T CD4+ muestran una producción de citocinas que usualmente sigue tres patrones distintos y estereotipados; estos patrones son producidos por subpoblaciones discretas que se denominan Th1, Th2 y Th0. Las células Th1 secretan principalmente interferón- (IFN-), interleucina-2 (IL-2) y factor de necrosis tumoral (FNT), citocinas que tienen un papel clave en la respuesta inmune mediada por células y el fenómeno de hipersensibilidad de tipo tardío. Las células Th2 producen IL-4, IL-5, IL-6, IL-9, IL-10 e IL-13, las cuales juegan un papel clave en la generación de la respuesta inmune humoral. Existe una regulación negativa recíproca entre las células Th1 y Th2 ya que ciertas citocinas de las primeras (principalmente IFN-) y de las segundas (IL-4, IL-10) tienen un efecto inhibitorio sobre células Th2 y Th1 respectivamente. Las células Th0 producen citocinas tipo Th1 y Th2. Es posible determinar el patrón de citocinas que están siendo producidas en un tejido, lo que permite inferir si ocurre una activación preferencial de células Th1, Th2 o Th0 en ese sitio. La activación preferencial de subpoblaciones de linfocitos CD4+ tiene un papel importante en la patogenia de enfermedades infecciosas y autoinmunes. Los pacientes con lepra lepromatosa tienen una activación preferencial de células Th2, lo cual conduce a una enfermedad diseminada con ausencia de respuesta inmune celular. La activación preferencial de células Th2 puede ser de importancia en la patogenia de enfermedades autoinmunes generalizadas, en tanto que las células Th1 tienen importancia en padecimientos autoinmunes órgano-específicos. Resulta factible el manipular in vivo la activación preferencial de linfocitos Th1 y Th2, lo cual puede tener implicaciones terapéuticas importantes


Sujet(s)
Dosage biologique , Test ELISA , Lymphocytes T/physiologie , Lymphocytes T/immunologie , Technique de Western , Technique de Northern , Réaction de polymérisation en chaîne , Cytokines/classification , Système immunitaire/cytologie , /physiologie , Cellules/immunologie , Hybridation d'acides nucléiques/méthodes , Techniques immunologiques
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE